Standout Papers

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in mod... 2010 2026 2015 2020 1.1k
  1. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy (2010)
    Lee Honigberg, Ashley M. Smith et al. Proceedings of the National Academy of Sciences

Immediate Impact

4 by Nobel laureates 23 from Science/Nature 73 standout
Sub-graph 1 of 20

Citing Papers

Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
2024 StandoutScience
Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
23 intermediate papers

Works of Erik Verner being referenced

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors
2017
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
2010 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Erik Verner 1294 880 409 582 29 2.5k
Zhengying Pan 1279 1370 676 824 42 3.0k
Mint Sirisawad 1233 938 334 754 38 2.3k
Michael R. Grever 919 1640 342 1196 43 3.3k
Stephen K. Tahir 2352 336 334 302 34 3.2k
Carlo M. Croce 2345 488 160 315 31 3.6k
Luca Mologni 1703 774 1066 397 90 3.3k
Brian E. Schultz 861 413 188 261 33 1.8k
Steven W. Elmore 3127 460 504 414 37 4.7k
Pingda Ren 2236 304 245 176 49 3.1k
Judy Lucas 2214 470 431 286 68 4.0k

All Works

Loading papers...

Rankless by CCL
2026